DK3144394T3 - SRM/MRM-test for trunkeret HER2 - Google Patents

SRM/MRM-test for trunkeret HER2 Download PDF

Info

Publication number
DK3144394T3
DK3144394T3 DK16195288.2T DK16195288T DK3144394T3 DK 3144394 T3 DK3144394 T3 DK 3144394T3 DK 16195288 T DK16195288 T DK 16195288T DK 3144394 T3 DK3144394 T3 DK 3144394T3
Authority
DK
Denmark
Prior art keywords
srm
truncated her2
mrm
test
mrm test
Prior art date
Application number
DK16195288.2T
Other languages
English (en)
Inventor
David B Krizman
Original Assignee
Expression Pathology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Expression Pathology Inc filed Critical Expression Pathology Inc
Application granted granted Critical
Publication of DK3144394T3 publication Critical patent/DK3144394T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00Chemical aspects of mass spectrometric analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/62Detectors specially adapted therefor
    • G01N30/72Mass spectrometers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/62Detectors specially adapted therefor
    • G01N30/72Mass spectrometers
    • G01N30/7233Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK16195288.2T 2010-12-08 2011-12-08 SRM/MRM-test for trunkeret HER2 DK3144394T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42120610P 2010-12-08 2010-12-08
EP11847217.4A EP2649192A4 (en) 2010-12-08 2011-12-08 SRM / MRM TEST FOR TRUNKED HER2

Publications (1)

Publication Number Publication Date
DK3144394T3 true DK3144394T3 (da) 2019-05-13

Family

ID=46207754

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16195288.2T DK3144394T3 (da) 2010-12-08 2011-12-08 SRM/MRM-test for trunkeret HER2

Country Status (8)

Country Link
US (2) US9765380B2 (da)
EP (2) EP3144394B1 (da)
JP (2) JP2014503811A (da)
AU (2) AU2011338281A1 (da)
CA (1) CA2820908A1 (da)
DK (1) DK3144394T3 (da)
ES (1) ES2719427T3 (da)
WO (1) WO2012078934A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2719427T3 (es) 2010-12-08 2019-07-10 Expression Pathology Inc Análisis cuantitativo de formas truncadas de HER2 por la técnica SRM/MRM
KR102067327B1 (ko) * 2015-05-29 2020-02-11 익스프레션 패톨로지, 인크. 최적의 암 치료를 위한 Her2 단백질 정량
WO2017100663A1 (en) * 2015-12-09 2017-06-15 Expression Pathology, Inc. Improved methods for treating her2-positive breast cancer
US20180172690A1 (en) * 2016-04-20 2018-06-21 Expression Pathology, Inc. Method for improved hepatocellular cancer diagnosis
US10725045B2 (en) 2018-02-13 2020-07-28 Nantomics, Llc Quantifying MGMT protein for optimal cancer therapy of glioblastoma
KR20200087700A (ko) * 2019-01-11 2020-07-21 난토믹스, 엘엘씨 질량 분석법에 의한 sdhb 단백질 발현의 평가
US20220221460A1 (en) * 2019-03-08 2022-07-14 Seoul National University R&Db Foundation Method of quantifying her2 in breast cancer sample by mass spectrometry and scoring her2 status using the same
KR102221206B1 (ko) * 2019-03-08 2021-03-02 서울대학교산학협력단 유방암 샘플에서 질량분석법 의한 her2 정량 방법 및 이를 이용한 her2 상태 스코어링
KR102370435B1 (ko) * 2019-11-22 2022-03-04 서울대학교산학협력단 유방암의 아형 분류에 사용되는 단백질의 질량분석기 기반 정량 방법 및 그 용도
KR102325731B1 (ko) * 2020-01-15 2021-11-15 주식회사 베르티스 암의 진단용 조성물
WO2021145479A1 (ko) * 2020-01-15 2021-07-22 (주)베르티스 암의 진단용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183497B1 (en) 1998-05-01 2001-02-06 Sub-Q, Inc. Absorbable sponge with contrasting agent
UA66370C2 (en) 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
AU2087401A (en) * 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
CN1146672C (zh) 2000-09-12 2004-04-21 日本钢管株式会社 超高强度冷轧钢板及其制造方法
US20040121946A9 (en) 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US20090197852A9 (en) 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
GB0208331D0 (en) * 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
DE10232570A1 (de) 2002-07-18 2004-03-04 Agfa-Gevaert Ag Identitätskarte
CA2511775A1 (en) 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1,-a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
CA2529863A1 (en) 2003-06-17 2004-12-23 Vib Vzw Peptide combos and their uses
US7322387B2 (en) 2003-09-04 2008-01-29 Freeport-Mcmoran Energy Llc Reception, processing, handling and distribution of hydrocarbons and other fluids
EP1883705A4 (en) 2005-05-25 2009-02-25 Expression Pathology Inc MULTIPLEX PROCESS FOR INCREASING PROTEOMIC COVERAGE FROM HISTOPATHOLOGICALLY TREATED BIOLOGICAL SAMPLES USING LIQUID TISSUE PREPARATIONS
WO2006127861A2 (en) * 2005-05-25 2006-11-30 Expression Pathology, Inc. Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
DE102006010111A1 (de) 2006-02-28 2007-08-30 Siegfried Gutfleisch Einrichtung zur Energieversorung von Gebäuden unter Nutzung der Sonnenenergie als Energiequelle
ES2288115B1 (es) 2006-05-03 2008-09-16 Figueras International Seating S.A. Sistema de desplazamiento de conjuntos de butacas.
US20090253156A1 (en) * 2006-05-05 2009-10-08 Perkinelmer Las, Inc. Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases
ES2365948T3 (es) 2006-11-16 2011-10-13 François MERZ Dispositivo de visión binocular.
WO2008074067A1 (en) 2006-12-18 2008-06-26 Macquarie University Detection and quantification of polypeptides using mass spectrometry
WO2008097229A1 (en) 2007-02-09 2008-08-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Method for spectroscopic quantitation of her-2 in biological samples
CA2694120A1 (en) * 2007-06-22 2008-12-31 Expression Pathology Method of discovering and analyzing secreted biomarkers of disease from solid tissue
US8604692B2 (en) * 2007-11-06 2013-12-10 Translational Therapeutics, Inc. Mass spectrometry assay for eIF4E and eIF4E regulon activity
US8470542B2 (en) * 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
EP2588144B1 (en) * 2010-07-02 2018-05-09 Ventana Medical Systems, Inc. Detecting targets using mass tags and mass spectrometry
ES2719427T3 (es) 2010-12-08 2019-07-10 Expression Pathology Inc Análisis cuantitativo de formas truncadas de HER2 por la técnica SRM/MRM
KR102067327B1 (ko) 2015-05-29 2020-02-11 익스프레션 패톨로지, 인크. 최적의 암 치료를 위한 Her2 단백질 정량
WO2017100663A1 (en) 2015-12-09 2017-06-15 Expression Pathology, Inc. Improved methods for treating her2-positive breast cancer

Also Published As

Publication number Publication date
JP2014503811A (ja) 2014-02-13
AU2016259294B2 (en) 2018-11-01
US20180187239A1 (en) 2018-07-05
US9765380B2 (en) 2017-09-19
WO2012078934A2 (en) 2012-06-14
EP2649192A2 (en) 2013-10-16
EP3144394B1 (en) 2019-02-06
EP3144394A1 (en) 2017-03-22
JP2018013492A (ja) 2018-01-25
ES2719427T3 (es) 2019-07-10
CA2820908A1 (en) 2012-06-14
EP2649192A4 (en) 2014-05-14
WO2012078934A3 (en) 2012-08-02
US10577641B2 (en) 2020-03-03
AU2011338281A1 (en) 2013-07-11
US20130302328A1 (en) 2013-11-14
AU2016259294A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
FIC20250029I1 (fi) neratinibi
DK3144394T3 (da) SRM/MRM-test for trunkeret HER2
FIC20230025I1 (fi) neratinibi
SMT201600289B (it) Nuove immunoadesine ctla4-ig
EP2652776A4 (en) Wafer inspection
DK3661211T3 (da) Billedforudsigelse-afkodningsfremgangsmåde
DK3241558T3 (da) Højopløselige leptiner
IL221719A (en) Biomarkers for theranostics
DK3189862T3 (da) Påfyldningsføringslumen
PT2552242E (pt) Resumo
DK3514519T3 (da) Testkassetter
BR112013012755A2 (pt) projetor
UA21334S (uk) Цукерка
AT10812U2 (de) Prüfstandsanordnung
AT10813U2 (de) Prüfstandsanordnung
DE112011102774A5 (de) Antriebsstrang
DK2568854T3 (da) Sædeindretning
GB201010891D0 (en) Inspection
EP2623153A4 (en) INTERCONNECTS
EP2584243A4 (en) INTERCONNECTS
FI20105110A0 (fi) Refraktometri
DE112011101867B8 (de) Fahrzeugfunktionsprüfstand
EP2530457A4 (en) Defect inspection device
IL233569A0 (en) Srm/mrm assay for the insulin receptor protein
DE112011102622T8 (de) Gecrimpter Anschluss